[
  {
    "ts": "2025-12-18T00:16:32+00:00",
    "headline": "Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound",
    "summary": "Biogen (BIIB) has quietly outperformed the market over the past 3 months, with shares up about 20%. This performance has put the stock back on investor radars after a stretch of weaker multi year returns. See our latest analysis for Biogen. That 19.6% 3 month share price return stands out against a still modest 14.7% year to date share price gain and a disappointing 3 year total shareholder return of around negative 40%. This suggests sentiment has only recently started to warm up again. If...",
    "url": "https://finance.yahoo.com/news/biogen-biib-reassessing-valuation-recent-001632146.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ca9352ae-10d1-3760-bb71-e7973d751581",
      "content": {
        "id": "ca9352ae-10d1-3760-bb71-e7973d751581",
        "contentType": "STORY",
        "title": "Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound",
        "description": "",
        "summary": "Biogen (BIIB) has quietly outperformed the market over the past 3 months, with shares up about 20%. This performance has put the stock back on investor radars after a stretch of weaker multi year returns. See our latest analysis for Biogen. That 19.6% 3 month share price return stands out against a still modest 14.7% year to date share price gain and a disappointing 3 year total shareholder return of around negative 40%. This suggests sentiment has only recently started to warm up again. If...",
        "pubDate": "2025-12-18T00:16:32Z",
        "displayTime": "2025-12-18T00:16:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-biib-reassessing-valuation-recent-001632146.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-biib-reassessing-valuation-recent-001632146.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]